Skip to Main Content

Paper Details

Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
Bone Marrow Transplant
2
2022
Author NameAffiliation
John F DiPersioWashington University School of Medicine in St. Louis
  • 1 - 1

Datasets

Release 1.2